Comment
Towards a neuroimaging biomarker for amyotrophic lateral sclerosis

https://doi.org/10.1016/S1474-4422(11)70049-7Get rights and content

References (5)

There are more references available in the full text version of this article.

Cited by (139)

  • Cortical and subcortical grey matter atrophy in Amyotrophic Lateral Sclerosis correlates with measures of disease accumulation independent of disease aggressiveness

    2022, NeuroImage: Clinical
    Citation Excerpt :

    Therefore, reliable biomarkers are needed that allow continuous and objective assessment of ALS pathology and progression. The opportunity of neuroimaging to support diagnostics, staging, and therapeutic monitoring in ALS, led to international joined efforts, notably the Neuroimaging Society in Amyotrophic Lateral Sclerosis (NiSALS) (Turner et al., 2011). Nevertheless, discrepancies remain between the measurements derived from Magnetic Resonance Imaging (MRI) and the individual ALS disease course (Steinbach et al., 2018; Verstraete et al., 2015).

View all citing articles on Scopus
View full text